Pharma AI Tracker

CSL announced a collaboration with AWS to bring AI and cloud technology into research and clinical development. The release says the work aims to link lab and computational work more closely and to cut manual effort in protocol authoring, clinical data handling and regulatory submissions, while keeping data governance, traceability and inspection readiness. It names AWS as the principal AI and cloud provider, including services such as Amazon Bedrock.

Partners: Amazon Web Services

Earendil Labs announced a research collaboration with Genentech (Roche Group) to discover bispecific antibodies in oncology using Earendil's AI-driven biologics platform; Earendil reports $55 million upfront and potential value above $1.5 billion.

Partners: Earendil Labs

AbbVie and Iambic announced a multi-year collaboration using Iambic's AI discovery platform to find small-molecule candidates in immunology, neuroscience and oncology.

Partners: Iambic

A text-to-SQL agent built by Novo's Rare Disease Insights & Analytics team that answers plain-language business questions from claims and prescription data.

Partners: Dataiku

A collaboration to test Anthropic's Claude Science on chosen R&D problems and use Anthropic models for AI-assisted software engineering.

Partners: Anthropic

Two Agentforce agents: SEIMEI condenses clinical literature and field conversation notes into insights, and AIMI drafts cited answers to healthcare professionals' medical questions for staff to review.

Partners: Salesforce

Otsuka Holdings' Integrated Report 2026 says technology validation has started to expand the Cysteinomix drug discovery platform using generative AI. In the same report, Taiho Pharmaceutical's Tsukuba discovery division says it is working to introduce robotics and AI in the search for drug targets and compound design while expanding Cysteinomix.

Otsuka Holdings' Integrated Report 2026 states that Astex is using a proprietary dataset of more than 19,000 protein-ligand complexes to develop computational co-folding capabilities called AstexFold and generative AI models for fragment-based and structure-based drug design. The report also mentions the Pyramid platform integrating AI/ML methods. This is company self-reported, and the report does not state a deployment stage.

BenchSci announced a two-year enterprise agreement for argenx scientists to use EMET, its agentic research environment, in preclinical, computational and drug development workflows; argenx is quoted as testing whether it can accelerate preclinical development.

Partners: BenchSci

Takeda is deploying Weave Bio's AI regulatory-writing platform across 14 programs. Use started with IND drafting and has grown to health-authority question responses.

Partners: Weave Bio

Vendor blog recapping a Roche talk: ThoughtSpot says Roche scaled to 500 active users of ThoughtSpot's Spotter AI analytics agent within a year, and has 40,000+ ThoughtSpot users overall.

Partners: ThoughtSpot

Noetik says it met the first milestone of its five-year licensing agreement with GSK (announced January 2026, $50 million upfront capital and near-term milestones) and that GSK teams are using its OCTO-VC models for virtual cell experiments, patient stratification and H&E data enrichment.

Partners: Noetik

Veeva announced that Regeneron has committed to Veeva Vault CRM globally. Veeva says Regeneron's plan is to generate Commercial Evidence via AI-powered field engagement.

Partners: Veeva Systems

Hengrui's 2026 half-year report says the company uses an integrated data-analysis platform to read clinical demand and uses AI tools to deliver medical information through personalized academic communication, in order to improve prescription conversion, with compliance traceability across the process.

A lab-in-the-loop system built with AWS that gives discovery AI agents shared memory of past experiments. Sanofi aims to halve the number of molecules needing wet-lab validation.

Partners: AWS

Nucleai says it has used AI to analyze H&E and IHC whole-slide images from several Gilead oncology clinical studies in support of Gilead's ADC clinical programs, generating candidate spatial biomarkers.

Partners: Nucleai

UiPath announced that Merck KGaA, Darmstadt, Germany is building a program for agentic software testing on UiPath Test Cloud, applying AI agents, automation and human oversight across the software testing lifecycle.

Partners: UiPath

UCB says it worked with MPIRIQ to explore AI-supported identification and referral of patients with suspected axial spondyloarthritis, and that the teams evaluated a referral pathway that uses AI.

Partners: MPIRIQ

UCB says IB Lab FLAMINGO, an AI platform that was originally a UCB initiative, detects vertebral fractures on routine CT scans and is already validated across European health systems. The article says UCB and ImageBiopsy Lab designed and validated a downstream osteoporosis care pathway for patients the tool identifies.

Partners: ImageBiopsy Lab

Novo named AWS its preferred cloud and strategic AI partner. It plans to use Amazon Bio Discovery for target and therapy design and Bedrock AgentCore for AI agents across operations.

Partners: AWS

AstraZeneca authors describe Research Assistant, an internal LLM tool for exploring biomedical questions, and share lessons from running it at scale in R&D.

Recursion reports that a joint Recursion-Genentech team identified and validated a first target from an AI-driven neuroscience map, now advancing into a joint small-molecule early discovery program.

Partners: Recursion

Awarathon says Sun Pharma used its AI-powered roleplay assessments and AI-enabled reports to train medical representatives, starting with two divisions at pilot stage and then rolling the platform out across all India business verticals, with teams in South Africa, Bangladesh and Nepal also adopting it.

Partners: Awarathon

Novo will use H1's AI-powered data to improve trial design, site selection and enrollment. H1 also takes rights to advance Novo's in-house StudyHub platform.

Partners: H1

On its Q2 2026 earnings call Pfizer said AI is already lowering manufacturing costs and improving yields.

Uncountable announced that Merck KGaA, Darmstadt, Germany selected its platform to digitalize its central analytical laboratories; Uncountable says the solution will improve data access to enable ML- and LLM-powered use cases.

Partners: Uncountable

Relation announced a strategic research collaboration with GSK to generate large-scale human cellular perturbation data and deploy it into models including MORGAN, its cellular biology foundation model; Relation reports up to $110 million in upfront and success-based milestone payments.

Partners: Relation

In its second-quarter 2026 results, Alnylam said it had announced a collaboration with a large health care system in California to support that system's DETECT-ATTR study. The study evaluates Invision Precision Cardiac Amyloid, described as an AI-enabled, FDA-cleared echocardiography screening approach for cardiac amyloidosis.

In the same results release, Alnylam said it had expanded its strategic partnership with Komodo Health to scale Marmot, which Alnylam describes as Komodo's analytics AI platform, across key enterprise functions at Alnylam.

Partners: Komodo Health

Evinova announced a multi-year collaboration under which Merck KGaA, Darmstadt, Germany will adopt its AI-native platform across study design, document authoring and downstream automation in clinical development.

Partners: Evinova

Novartis says its teams use AI-enhanced analytics to surface early risk signals across trial supply, monitoring and recruitment and to recommend next-best actions.

Novartis says generative AI can create well-structured first drafts of clinical and regulatory documents from approved sources, which Novartis experts then review and refine.

Novartis says that with generative approaches its teams can propose new molecular structures informed by protein information and prior chemistry and optimize multiple properties in parallel.

Incyte's quarterly report for the period ended 30 June 2026 says that in May 2026 the company entered a license, research and collaboration agreement with Genesis Molecular AI covering the building and deployment of artificial intelligence to accelerate discovery of novel molecules. Under the agreement, Incyte will identify targets and Genesis will use the Genesis Exploration of Molecular Space artificial intelligence platform to identify molecular structures for each target. The filing says Incyte paid Genesis $120.0 million, made up of an $80.0 million upfront payment and a $40.0 million equity investment.

Partners: Genesis Molecular AI

Incyte's second-quarter 2026 earnings release says that in May the company expanded its use of artificial intelligence across discovery and development, including a strategic collaboration with Edison Scientific to employ Edison's AI scientist Kosmos.

Partners: Edison Scientific

Cognizant says Novartis selected it for a five-year, AI-enabled integrated IT operations engagement using agentic AI.

Partners: Cognizant

BMS will expand its NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems to train proprietary foundation models, building on nearly three years of NVIDIA collaboration.

Partners: NVIDIA

BMS says agents automate target identification as well as validation, saving weeks of manual work for its scientists.

Under its Predict First approach, BMS says AI-generated predictions inform the design of every small-molecule program and most large-molecule programs before bench work.

A multi-year collaboration, first signed in December 2023, that uses Aqemia's generative AI and physics-based platform to design small molecules. It was expanded in July 2026 with a new target nomination.

Partners: Aqemia

Chai Discovery announced a collaboration agreement giving argenx access to its AI platform to apply de novo antibody discovery across therapeutic targets.

Partners: Chai Discovery

Chai Discovery announced a collaboration giving Novartis access to Chai's AI models, including Chai-3, for antibody discovery across multiple targets.

Partners: Chai Discovery

Trade press reported that Moderna showed Lucy, an internal machine-learning platform that runs closed-loop lab experiment cycles, at its 2026 Science Day.

Partners: OpenAI

Sun Pharma's FY26 annual report says the company expanded the use of digital and AI-enabled tools across manufacturing, commercial and corporate functions to support planning, productivity and execution.

A collaboration using Insilico's generative AI Pharma.AI platform to find drug candidates across Takeda's therapeutic areas.

Partners: Insilico Medicine

Daiichi Sankyo says it has introduced advanced AI models, including OpenFold-3, into its internal environment and provides them to researchers as cloud applications, adjusting models with the research organization so AI can be used in actual drug-discovery work.

Daiichi Sankyo says it has introduced AI agents into bioinformatics work and is using them to make exploration and analysis of life-science data more efficient and more advanced, while checking their usefulness on actual analysis work.

Daiichi Sankyo says that, on its integrated data analysis platform, it provides an environment in which employees who are not engineers or data scientists can search and analyze clinical-trial information in everyday language by incorporating AI functions.

Daiichi Sankyo says that, going forward, it is renewing its safety database into a next-generation database that incorporates automation by AI, in order to make global pharmacovigilance operations more efficient and to strengthen analysis.

As part of its smart research lab work, Daiichi Sankyo says it has built AI into experimental equipment so that liquid-volume measurement and checks of the boundary between liquids, previously done by eye, can be done automatically in real time.

Daiichi Sankyo says that, as one part of its Healthcare-as-a-Service work, it has launched ReTabell, an AI-equipped menu-support site.

Jazz's 2025 sustainability report says the company introduced MOMENTUM in 2025, a clinical trial toolbox for patient-representation insights. It says MOMENTUM draws on large language model technology to help teams design more representative trials and recruit patient populations that reflect true disease epidemiology.

Jazz's 2025 sustainability report says that in 2025 the company formally established an AI Council for cross-functional governance and oversight of AI use, and that it established AI Responsible Use Guidelines to define expectations and support consistent application.

Jazz's 2025 sustainability report says that in the fourth quarter of 2025 the company launched an enterprise-wide AI Literacy platform to build foundational capability across the workforce.

A research capability combining data, AI and machine learning, automation and robotics to speed discovery, presented at Moderna's 2026 Science Day.

Bayer and Iambic announced a drug-discovery collaboration in which Bayer will use Iambic's AI-driven platform. The collaboration is focused on small-molecule discovery.

Partners: Iambic

A tool that analyzes multimodal data to simulate trials before they start, forecasting cycle times, patient burden and cost drivers.

An in-silico trial platform built on Sanofi disease-biology models and clinical data. It is meant to predict safety, efficacy and trial outcomes to inform go/no-go decisions.

Applies AI-assisted review and validation to clinical results once data become available.

A digital and AI solution that streamlines transfer of new drugs or indications from R&D to industrial-scale manufacturing.

A shop-floor AI solution aimed at improving equipment reliability, continuity and quality across production systems.

An AI tool for reviewing scientific literature. Sanofi reports accuracy above 95% and much shorter review times.

An AI-powered energy management platform that helps optimize energy consumption in real time.

Sanofi's internal platform for building AI, used by its data and AI developers.

City A.M. reports that GSK's director of AI and machine learning told London Tech Week that agentic AI is already affecting every asset in the R&D pipeline and is a live operational tool.

The same City A.M. report says GSK is using generative AI to scan internal and external datasets, including literature, bench results and clinical trials, to try to match a treatment to an individual patient.

A multi-year deal to co-develop biopharma AI agents with Owkin, backed by a five-year licence to Owkin's K Pro AI scientist.

Partners: Owkin

Alnylam and Inceptive Nucleics announced a strategic collaboration, valued at up to $2B with upfront consideration of $30M, pairing Alnylam's RNAi platform and proprietary siRNA data with Inceptive's foundation models and AI expertise to accelerate nucleic-acid drug design.

Partners: Inceptive Nucleics, Inc.

AbbVie says AI is used daily in its manufacturing operations, including predictive equipment information and guiding robotics and automation with real-time shop-floor data.

AbbVie is piloting WRAP, a Whole Room AI Platform intended to act as a digital twin so factory staff can verify a manufacturing space meets required standards before operations begin.

An AI agent built on Snowflake Cortex AI that produces pre-call plans for sales reps before physician visits.

Partners: Snowflake

Sanofi is moving AI workflows directly onto its Snowflake data using Cortex AI and the Elementum workflow platform, pitched as AI replacing some applications.

Partners: Snowflake, Elementum

AstraZeneca built a supervisor-led multi-agent Brand Assistant on Databricks that gives commercial teams governed access to structured and unstructured data, growing from a small proof of concept to more than 20 agents in production.

Partners: Databricks

Lilly speakers at Databricks Data + AI Summit 2026 described the business and technology plan behind rolling out an AI assistant for field teams.

Partners: Databricks

Conversational AI analytics over a governed Snowflake commercial data layer that gives US field leaders faster answers on weekly performance changes.

Partners: Tellius, Snowflake

Pfizer scientists published a generative AI workflow that drafts pharmacokinetic sections of clinical study reports and scored its output against manually written reports.

An enterprise platform on Databricks that lets over 10,000 employees build, deploy and run AI agents under central governance, including a control tower, policy-enforcement agent and agent marketplace.

Partners: Databricks

Sanofi ran a small Copilot pilot but decided not to roll it out widely to employees, according to its chief digital officer.

Partners: Microsoft

Celltrion said it set up a dedicated AI-based new-drug organization the previous year and is applying AI in stages, with bioinformatics, to finding, validating and optimizing new-drug target candidates. The release also says the company is pursuing open innovation with external AI specialist firms, which it does not name.

Celltrion said manufacturing work is focused on smart factories that apply physical AI at new plants. It said it plans to raise automation at drug-substance plants 4 and 5, which are to be built in Songdo, with autonomous mobile robots, an automated warehouse, intelligent and collaborative robot arms, and manufacturing-management software.

Celltrion said it is already using AI in office work for data analysis, building dashboards and drawing insights, and that it will widen that use. A chatbot simulation on the electronic document system projected that time for simple tasks such as document search and comparison would be about 80 to 90 percent shorter.

Torrent's 2025-26 integrated report says the company is evaluating the deployment of end-to-end e-workflow systems for BA and BE studies, and advanced AI tools for literature screening. Only the literature-screening tools are described as AI.

Novo's global business services head said AI now drafts regulatory documents, analyzes safety data and supports commercial analytics, shortening the path from last patient visit to filing.

BMS announced a strategic agreement to deploy Anthropic's Claude, including Claude Code and agentic workflows, across research, development, manufacturing, commercial and corporate functions for more than 30,000 employees.

Partners: Anthropic

A custom AI agent that helps researchers test clinical hypotheses against proprietary trial data using AI-generated analysis. It is live internally with broader rollout under way.

Partners: Microsoft

Atinary's machine-learning experiment optimizer is being built into Takeda discovery workflows to speed up reaction and process optimization.

Partners: Atinary, AWS

A Takeda R&D Quality lead described a multi-agent AI system for preparing CDMO audit briefings. It was shown as a validation-feasibility study on synthetic data, not a production deployment.

Salesforce announced that CSL is expanding its collaboration to use Agentforce Life Sciences for Customer Engagement, an AI-powered platform, across its commercial and medical operations, including Seqirus.

Partners: Salesforce

Salesforce says CSL Plasma already uses Data 360 to unify donor data and is deploying Agentforce in order to enhance service delivery at the donor contact center.

Partners: Salesforce

Roche agreed to acquire PathAI, whose AI pathology platform will join Roche Diagnostics and support companion diagnostics and biopharma clinical-trial and translational services; closing expected H2 2026.

Partners: PathAI

Amgen describes using historical trial and real-world data to build a digital-twin synthetic control for each enrolled patient in AI-enabled trials.

Takeda programmers presented a framework that uses an LLM through Amazon Bedrock to review ADaM specifications and generate SAS code.

Partners: AWS

An AI quality-intelligence tool that began as a narrow pilot on deviation and complaint trending with suggested root causes, and is now used at several manufacturing sites.

Partners: Aily Labs

BeOne's 2026 shareholder letter says the company's in-house development model has integrated AI and automation, and that BeOne is expanding the use of AI to optimize clinical trial design and accelerate recruitment. The same passage says the company has already shortened protocol-development time, sped proof-of-concept decisions and improved clinical-trial site monitoring.

Sobi's first-quarter 2026 report says the company kicked off a learning journey for all employees aimed at accelerating smart and responsible use of digital tools, including AI, and that new learning resources and a shared learning channel were launched during the campaign week.

Moderna picked Salesforce's Agentforce Life Sciences for Customer Engagement to bring its global commercial operations onto one platform.

Partners: Salesforce

UCB and the University of Southampton announced DARC, a three-year effort to build an end-to-end in-silico platform for therapeutic antibody design. UCB's head of UK research says the partnership strengthens UCB's position in AI-enabled antibody design.

Partners: University of Southampton

J&J's CIO cited AI helping manufacturing teams decide the right time and temperature to add solvent during production.

J&J's CIO said AI now handles much of the preparation of clinical trial reports for regulators, cutting a job that took hundreds of hours to minutes.

J&J uses AI to screen chemical and biologic candidates and says this has halved lead optimization time and sped up two compounds.

Merck signed a multi-year deal with Google Cloud, worth up to about $1 billion, to roll out an agentic AI platform across R&D, manufacturing, commercial and corporate teams.

Partners: Google Cloud

At ISHLT 2026, United Therapeutics listed a presentation from its ex-vivo lung perfusion program on using machine learning for earlier, real-time predictions of whether a lung will be accepted for transplant during rc-EVLP.

BeOne's 2025 sustainability report says the company set budgetary targets to advance non-animal research tools through its in-house computational drug design and AI drug discovery groups. It says those groups now play an active role in every BeOne research program.

BeOne says it leverages assistive AI and digital tools to analyze safety data more efficiently and to speed the identification of potential risks. The statement sits in the report's description of its in-house global patient-safety and pharmacovigilance work.

A partnership to apply OpenAI's models from drug discovery to commercial operations and to upskill Novo's workforce.

Partners: OpenAI

Tempus announced an expanded collaboration giving Gilead enterprise-wide access to Tempus's AI-driven Lens platform and multimodal data for oncology R&D and real-world evidence.

Partners: Tempus AI

TriNetX and Regeneron announced a collaboration giving Regeneron access to TriNetX de-identified electronic health records; the release says the growing database will drive drug discovery and development and empower AI training algorithms for digital health solutions.

Partners: TriNetX

Insmed's 2025 annual report says that in early 2025 the company launched InQuiry, its proprietary generative AI assistant, which uses internal data to summarize documents, create content and produce meeting recaps. The report says InQuiry fully integrates across Insmed and is helping improve workflows, and that teams have realized productivity gains on tasks such as job descriptions, development plans and templates.

Insmed says it is leveraging AI for labor-intensive tasks that include determining next best actions for case managers on its Patient Services team, along with translating documents and producing HEOR dossiers. The same sentence says the company is exploring how AI may be used to write first drafts of IND applications and to assess business-development opportunities.

A generative AI chatbot built on Dataiku that answers field sales questions about incentive-compensation rules.

Partners: Dataiku

A Dataiku-built generative AI tool that assesses scientific literature for relevance and gaps for medical affairs.

Partners: Dataiku

At its March 31, 2026 R&D Day, Astellas said NVIDIA's AI-powered supercomputing for small-molecule drug design has already been implemented.

In the same R&D Day remarks, Astellas said it is introducing an AI-enabled protein station for research automation, as part of aiming to accelerate development of biopharmaceuticals and improve productivity.

In the same remarks, Astellas said gene therapy guided by AI will lead to precise organ targeting, reduced toxicity and enhanced treatment.

Astellas said that using Evinova's AI-native Study Designer will enable it to design more sophisticated, patient-centered clinical trials efficiently. In the question session, the R&D head described that study designer as a platform on which AI agents discuss protocol design.

Partners: Evinova

In the same R&D Day question session, Astellas said each team is already using AI to generate clinical study reports. The same answer says AI translation has sped translation of clinical-trial documents, with human confirmation still required.

BeOne says it recently convened a Patient Advocacy AI Innovation Lab with members of the blood-cancer community to discuss patient and caregiver needs, how to harness the technology, and how to guide patients in using AI tools. The same article says BeOne is using those insights to develop new digital tools to help patients, including people living with chronic lymphocytic leukemia, navigate their care.

Shionogi says the Artificial Intelligence Statistical Programming System, released in September 2023, enables AI to automatically generate the SAS statistical analysis programs required for clinical trials and achieved a 30% reduction in standard work hours.

Shionogi says the Generative AI Group, established in October 2024, is advancing the development, implementation and internal deployment of operational support systems that use generative AI. The same page says the company aims to use generative AI large language models for efficiency and quality in medical writing, including protocols and clinical study reports.

Hengrui's 2025 annual report says the company vigorously develops AI-driven drug discovery, which it abbreviates AIDD, and that AI technology is deeply integrated throughout its R&D pipeline.

Innovent's 2025 reporting says the company kept pushing an intelligent upgrade of its R&D system, and sped up the deep integration of artificial intelligence technologies across the whole drug development chain.

Innovent's 2025 ESG report describes an AI+NGS wet-dry closed-loop antibody discovery platform that has been applied to multiple internal projects, shortening the antibody screening cycle and improving the efficiency of discovering high-quality candidate molecules.

Innovent says it has developed an AI-driven de novo design closed-loop system dedicated to small protein drug development. The same report says the system enables intelligent iteration from target elucidation to molecular optimization and has demonstrated a magnitude-level improvement in hit rates and R&D iteration speed in internal projects.

During the reporting period, Innovent upgraded its learning platform, turning the original online training platform into iTalent, an AI-powered intelligent learning platform.

Innovent's 2025 ESG report says protective measures implemented in 2024 for the WeMol computing platform and AI intelligence repository were followed by a security baseline for the electronic lab notebook system covering the R&D computing environment.

Alnylam said it is partnering with Viz.ai to develop an AI-enabled ATTR-CM care pathway that combines an FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity. The release says the related AWARE study will launch at five pilot health systems later in 2026 to generate real-world evidence.

Partners: Viz.ai

insitro says BMS nominated two more ALS targets identified via insitro's AI-driven Virtual Human platform, expanding their collaboration.

Partners: insitro

Merck KGaA's 2025 annual report says the company also uses AIDDISON, its generative-AI discovery platform, internally in the Healthcare business for early-stage drug discovery.

Merck KGaA's 2025 annual report says myGPT Suite, its internal generative AI platform, has more than 32,000 active users a month (over half the workforce) and more than 90% cost savings versus off-the-shelf options.

Merck KGaA's 2025 annual report says its smartfacturing playbook, including modular manufacturing, AI energy optimization and predictive maintenance, cuts time to market by up to 50% and uses around 20% less energy at reference sites.

Merck co-developed KERMT with NVIDIA, a deep-learning model trained on millions of molecules to predict compound properties for drug discovery.

Partners: NVIDIA

Roche added 2,176 NVIDIA Blackwell GPUs on premises in the US and Europe, bringing its combined on-premise and cloud footprint to more than 3,500 GPUs, as the next phase of an NVIDIA collaboration begun in 2023.

Partners: NVIDIA

Roche and Genentech (gRED) run a Lab-in-the-Loop approach that connects biology and chemistry experiments with Roche's AI models, now enhanced with NVIDIA BioNeMo.

Partners: NVIDIA

Roche says digital twins of production lines, powered by NVIDIA Omniverse libraries, let engineers optimize processes and factory designs.

Partners: NVIDIA

Galderma's 2025 annual report says the year included a new Artificial Intelligence Steering Committee exploring advanced analytical methods on the Global Sensitive Skincare Faculty's epidemiological survey, described as the largest worldwide profiling study of sensitive skin, with more than 16,000 subjects.

Lilly's NVIDIA-built supercomputer for AI-driven research came online in early 2026 to support discovery and other scientific work.

Partners: NVIDIA

Sandoz's 2025 integrated report says the company is part of the EU-funded DRAIGON research consortium, which uses AI and genomics to predict resistance and support better treatment decisions, as one of its antimicrobial-resistance research projects.

Partners: DRAIGON consortium

Shionogi said a generative-AI solution for drafting regulatory documents in drug development was built by combining its medical writers' knowledge and its data scientists' AI design work with Hitachi's generative-AI know-how. A proof of concept at the company confirmed about a 50% reduction in clinical study report preparation time and about a 20% reduction in protocol preparation time. The same release says Shionogi licensed the solution to Hitachi, which began offering it to pharmaceutical and healthcare companies in Japan in February 2026.

Partners: Hitachi

plai supplies predictions and what-if scenarios to the R&D governance meetings where molecule progression decisions are taken.

Partners: Aily Labs

Sanofi says it uses machine learning and AI across R&D, including for writing clinical study reports. No tool or metrics are named on the page.

AI and machine-learning algorithms inside Moderna's design and ordering platform that optimize mRNA sequences for manufacturability and quality.

Sobi's capital markets presentation says AI improves physician engagement and supports world-class field-force effectiveness.

Under its AI agenda, Sobi's capital markets presentation includes applying data and AI to optimize supply and reduce cost of goods sold.

Sobi's capital markets presentation lists generative-AI authoring of clinical study reports and Module 2 on a map of technology it describes as enabling faster development-cycle time.

On the same technology map, Sobi lists AI-driven disease pathway understanding.

On the same technology map, Sobi lists a literature finder that uses AI beside its real-world-data insights platform.

Sobi says Florio, its rare-disease patient platform, has evolved into a platform generating real-world insights at scale and was co-created with patients and healthcare professionals using design expertise, digital technology and AI.

AstraZeneca, alongside Astellas and BMS, agreed to use and share operational data with Evinova's AI-native trial platform (an AstraZeneca health-tech business) to get benchmarks and recommendations that speed trials.

Partners: Evinova

Merck and Mayo Clinic agreed that Merck will use Mayo Clinic Platform's de-identified multimodal clinical and genomic data to validate AI models, including virtual-cell work, for target identification and early development choices.

Partners: Mayo Clinic

Genmab says it has expanded its scientific focus to use data science and AI to aid in the discovery of new targets and biomarkers and to bolster its precision medicine and translational laboratory capabilities.

Sanofi's internally hosted generative AI companion, launched in October 2024, that helps employees find answers, navigate tools and automate routine tasks. Sanofi says it supports more than 30,000 users.

An in-house AI tool that learns from past and current batch performance to push manufacturing yields higher. Sanofi estimates about EUR 10 million a year in savings from analyzing over 13,000 Lovenox batch runs.

An AI agent used to help optimize product launch plans.

An AI agent used to relieve bottlenecks in quality assurance workflows.

AI-driven target discovery engines in R&D. Sanofi says they produced seven new drug targets in a single year.

An AI tool used in manufacturing and supply to help decide how production batches are allocated.

Lilly modelled the steps of a manufacturing process as a high-fidelity digital twin to find ways to raise output, according to its CIDO.

Lilly uses AI to watch product on its lines and catch defects, per its CIDO.

Lilly's CIDO named demand forecasting as one of the business areas where the company applies AI.

A multi-year partnership that gives Takeda access to Iambic's AI discovery tools, including the NeuralPLexer protein-ligand model, initially for oncology and GI/inflammation programs.

Partners: Iambic Therapeutics

Vendor case study: Roche's patent organization built Lex, an agentic AI interface in Dataiku that orchestrates RAG, full-text and deep search for patent attorneys.

Partners: Dataiku

AstraZeneca bought Modella AI, following a 2025 collaboration, to bring its pathology foundation models and AI agents in-house for oncology R&D, including biomarker and targeted-therapy work.

Partners: Modella AI

Lilly and NVIDIA are setting up a joint Bay Area AI lab for drug discovery, with up to $1 billion invested over five years in people, infrastructure and compute.

Partners: NVIDIA

Sanofi's chief digital officer says Claude is central to its AI transformation and used daily by most employees.

Partners: Anthropic

Merck says it applies AI in clinical development to pick trial sites and to match and keep patients in studies.

Merck provides its field sales representatives with a generative AI chatbot to support their customer work.

Merck reports embedding AI throughout its content process, from idea generation through medical, legal and regulatory review.

Merck uses generative AI to produce supply chain risk assessments when disruptive events occur, reporting a turnaround of less than half an hour.

Pfizer and Boltz agreed to tune Boltz's open biomolecular foundation models on Pfizer's historical data into exclusive models and roll them out to Pfizer scientists for small-molecule and biologics design.

Partners: Boltz

Bayer announced a three-year collaboration and said it will integrate Cradle's generative AI platform into existing R&D workflows for antibody lead generation and optimization. Bayer says it selected Cradle after a successful proof of concept.

Partners: Cradle

Genmab announced a partnership with Anthropic. Under the agreement, the companies will design and deploy custom, Claude-powered agentic AI solutions to support Genmab's clinical development priorities.

Partners: Anthropic

A self-service platform that lets employees build their own chatbots on Amazon Bedrock foundation models. AWS reports about 2,500 chatbots and 25,000 employees using it.

Partners: AWS, Cloud2 Oy

A platform on Databricks for secondary use of completed clinical-trial data. It gives scientists and analysts access to billions of trial data points.

Partners: Databricks

Astellas says it actively uses artificial intelligence, automation and data science to optimize manufacturing processes, enhance quality management and improve operational efficiency. It says it is introducing work-support tools that use generative AI and data mining, and digital twins to simulate manufacturing processes and supply chains.

AI agents watch real-time equipment data to catch early signs of degradation and prevent unplanned downtime. More than 170 agents run across 45 systems at the Lessines site.

At its 2025 R&D day, Hengrui said AI-driven drug R&D has become an important innovation engine. It said it is relying on an AI target-discovery platform, an AI large-molecule design platform, an AI small-molecule generation and optimization platform, a specialized drug-research large model and AI drug-research agents to improve the efficiency of target discovery, molecule design and developability optimization.

Moderna was an early-access user of Veeva's AI agent that checks promotional content against guidelines before MLR review.

Partners: Veeva

AstraZeneca and Pangaea Data will co-develop a multimodal AI platform, using Microsoft and NVIDIA technology, that finds undiagnosed or under-treated patients and surfaces therapy and trial options inside clinical workflows.

Partners: Pangaea Data, Microsoft, NVIDIA

Vendor case study: AWS says CSL used the agentic AI capabilities of AWS Transform to coordinate a phased migration of its on-premises environment to AWS.

Partners: Amazon Web Services

An AWS case study says CSL's Deviation AI uses AI-powered analytics to find deviations or outliers in trial outcomes so those trials can be evaluated and adjusted faster. The same page says the data platform that will support this work will be operational, so this is not described as already live.

A Lilly speaker at AWS re:Invent 2025 described a multi-agent system that lets non-technical staff query healthcare datasets in plain language, shortening data evaluation from months to weeks.

Partners: AWS

A custom LLM application that drafts informed consent forms from a trial protocol and template, with human review. Vertex data scientists report it has supported more than ten trials.

Microsoft reports that Pfizer has built and deployed more than 300 Copilot Studio agents across the company.

Partners: Microsoft

Vendor case study: Weights & Biases says GSK and Microsoft collaborated on AIGA, an internal framework for generative AI and agentic solutions.

Partners: Microsoft, Weights & Biases

Vendor case study: Weights & Biases says GSK built manufacturing digital twins at three levels of sophistication, with real-time sensors feeding ML workflows that predict batch trajectories, and that GSK has optimized 13 key products this way.

Partners: Weights & Biases

Weights & Biases says GSK now uses agents that detect anomalies, present root-cause hypotheses to the brand manager and simulate downstream scenarios, in an agentic supply-chain setup built with Microsoft.

Partners: Microsoft, Weights & Biases

Weights & Biases says GSK replaced a two-person check of environmental petri dishes with a one-person-plus-AI deep-learning system, operating across nine manufacturing sites and about 3 million images a year.

Partners: Weights & Biases

MSD and AWS explored a retrieval-augmented generative AI approach to help investigators handle manufacturing deviations, keeping generation to lower-risk steps with human oversight.

Partners: AWS

Teva unveiled Teva Rise, an open innovation platform that connects startups with Teva around technologies including AI, industry 4.0 smart manufacturing, digital health and biotech. The first cohort is a set of challenges for partners, not a statement that those AI systems are already running.

GSK and the Fleming Initiative announced six Grand Challenges, funded from GSK's GBP 45 million pledge, that use technologies including advanced AI. One programme will build an AI/ML model to design antibiotics for multi-drug-resistant Gram-negative bacteria, and another will build AI models that predict how drug-resistant pathogens emerge and spread.

Partners: Fleming Initiative

A multi-agent assistant built with Azure Logic Apps Agent Loop that pulls knowledge from many internal systems and helps employees find information faster.

Partners: Microsoft

Vertex's CEO said AI is helping streamline work such as preparing regulatory filings, which usually take six to nine months. Reported secondhand from a public event.

Microsoft says UCB created SKAI, a generative-AI platform, and that SKAI powers a family of AI assistants from medical writing to clinical statistics. On the same page a UCB speaker anticipates Microsoft 365 Copilot active use moving from 50% of employees to 80%.

Partners: Microsoft

At its Breda plant Amgen uses cameras, analytics, chatbots over maintenance reports and ML disruption prediction to run operations more efficiently.

Takeda is the founding partner in TetraScience's program to re-platform scientific data for AI use in R&D and CMC.

Partners: TetraScience

An AI assistant trained on Takeda's internal investigation standard that helps staff write more consistent deviation investigation reports.

Sequantrix announced an agreement with argenx for the use of its AI-driven DiseaseDecoder technology, a computational framework for identifying and evaluating targets.

Partners: Sequantrix

A second multi-year deal applying Nabla Bio's generative Joint Atomic Model to design antibodies and other protein drugs for Takeda's early programs.

Partners: Nabla Bio

AbbVie uses AI- and ML-powered analytics on decades of historical data to predict which clinical trial sites will activate quickly.

AstraZeneca runs a company-wide AI upskilling programme, and employees who reach a set accreditation level get early access to an internal AI agent builder, which produced over 1,500 agents in two months.

An in-house generative AI documentation platform built on Claude via Amazon Bedrock with MongoDB Atlas for drafting regulatory documents such as clinical study reports. Anthropic reports large time savings.

Partners: Anthropic, AWS, MongoDB

A field platform that gives sales reps AI-generated views of each doctor's patient population, prescribing patterns and access barriers. It was an award finalist write-up, not a Takeda release.

Takeda joined a federated effort to fine-tune the OpenFold3 structure-prediction model on proprietary protein-ligand data without sharing the data itself.

Partners: Apheris, AlQuraishi Lab (Columbia)

On its risk-management page, Shionogi lists business-model and operations reform through practicing AI drug discovery among the responses to its digital-transformation risk.

The same risk-management list includes market inventory prediction using AI as part of Shionogi's business-model and operations reform.

Merck KGaA's Life Science business signed an MoU with Siemens; joint projects include developing AI-driven tools and digital interfaces that simplify complex scientific processes.

Partners: Siemens

Merck signed a deal worth up to $349 million under which Variational AI tunes its generative chemistry platform on Merck data to design small molecules for two Merck-chosen targets.

Partners: Variational AI

GSK announced a new $1.2 billion US investment in advanced manufacturing facilities and AI and advanced digital technologies, including new AI and digital capabilities across its five existing US manufacturing sites.

Lilly launched TuneLab, giving biotech companies access to its drug discovery AI models through a third-party hosted, federated-learning setup that protects each party's data.

Gilead broke ground on a biologics Technical Development Center it says will feature digitally enabled systems, autonomous robotics and real-time monitoring. The company describes the site as one of the biopharma industry's most AI-enabled centers.

Galderma says its lead for Automation and AI has been building Galderma's AI Framework and establishing an AI Center of Excellence. The article quotes him saying predictive and generative AI are helping the company accelerate research and development, anticipate trends, personalize experiences and drive digital transformation.

Galderma says tech teams at its Uppsala manufacturing and R&D facility are using a custom-built AI interface to analyze handwritten documents, so that 30 years of historical R&D data can support new experiments and new products.

Revolution Medicines said it had recently announced a drug-discovery collaboration with Iambic Therapeutics in which Iambic will use its AI capabilities to generate customized models trained on Revolution Medicines' proprietary data. The release says the collaboration aims to enhance lead discovery and optimization against current and new drug targets.

Partners: Iambic Therapeutics

Takeda's Japan manufacturing and supply unit brought in an AI demand-forecasting model for production planning. It replaces a mostly history-and-expert approach.

Amgen adopted OpenAI's ChatGPT Enterprise early and widened access across the company in phases, with security controls.

Partners: OpenAI

AstraZeneca built Development Assistant on AWS, a multi-agent tool that lets development teams ask plain-language questions of their data and get answers quickly.

Partners: AWS

An enterprise rollout of Microsoft Copilot starting in early 2024 that reached about 20,000 employees. Users saved about 2.17 hours a week on average.

Partners: Microsoft

Otsuka Pharmaceutical, K.K. eMind and Tohoku University announced Phase II of the Epilepsy Smart Medical collaborative research project. The release says the project applies eMind's AI prediction technology to epilepsy and that its objective is to support patients through digital devices and AI. Otsuka joined Phase II in April 2025.

Partners: K.K. eMind, Tohoku University

UC Santa Cruz reports that argenx and Unnatural Products entered a multi-target collaboration using UNP's platform, which combines AI-guided compound design, parallel synthesis and direct-to-biology screening, with up to about $1.5 billion in potential payments to UNP.

Partners: Unnatural Products

Incyte's 2024 global responsibility report says that on Rare Disease Day the company launched The Unseen Journey, using generative artificial intelligence to illustrate the experiences of people living with myeloproliferative neoplasms. It says that as patients described their symptoms, generative AI created images of the hidden emotional and physical toll of those diseases, and that the stories and images were shared through 2024.

Merck built an internal generative AI tool that drafts clinical study reports for human review, more than halving first-draft effort, and has submitted CSRs produced this way.

A generative AI tool that helps write Sanofi's annual product quality reviews (PQRs). In June 2025 Sanofi reported about 3,500 PQRs a year and a target to cut creation time by 70 percent. An Aug 2024 Outsourced Pharma interview with Sanofi reported PQR writing about eightfold faster, a reported result and not a target.

Amgen process development staff use generative AI tools over a curated technical knowledge base of more than a million documents, with evaluations and risk-based validation.

A collaboration with NVIDIA to build custom AI models and agents for early research and clinical development on the Gefion AI supercomputer.

Partners: NVIDIA, Danish Centre for AI Innovation (DCAI)

Novo worked with Columbia University and AWS inside the OpenFold consortium to train the OpenFold3 protein-structure model.

Partners: AWS, Columbia University, OpenFold Consortium

In 2024, Viatris implemented emerging technology and artificial intelligence to improve adherence to compliance policy requirements by launching a new tool. The report describes that tool as chatbot-style policy search.

During 2024, Viatris continued exploring emerging technologies, including artificial intelligence, to potentially enhance product safety evaluation, communication and risk mitigation.

Merck KGaA and imec announced a partnership to develop a modular MPS-on-a-chip platform intended to simulate human body responses and provide high-quality training data for AI models in drug discovery.

Partners: imec

A strategy scorecard in Torrent's 2024-25 integrated report lists implementing AI tools for quality management systems.

Torrent's 2024-25 integrated report says the company is evaluating AI tools to optimise various regulatory and quality-related activities, with the stated aim of faster decision-making and improved compliance management.

Takeda chose Salesforce's AI-enabled Life Sciences Cloud to give commercial teams embedded insights for engaging healthcare professionals.

Partners: Salesforce

PharmaEssentia's 2024 annual report says its U.S. subsidiary continued to extend the drug's reach through AI technologies, together with social media, advocacy groups, clinic information displays and dedicated websites.

The PharmaEssentia Innovation Research Center site says its data science team uses an extensive database and employs AI and ML to select checkpoint-receptor targets. The same page says the center uses AI and machine learning to establish databases so it can select novel targets and patients more wisely and screen molecules faster.

In a talk summarised by OMP, J&J described its next-generation supply planning tool, including an AI assistant that surfaces insights for planners in real time.

Partners: OMP

Amgen's knowledge management team built a Q&A agent in Copilot Studio that searches the company's large body of R&D documents and reports.

Partners: Microsoft

Incyte's first-quarter 2025 update says that in February 2025 the company and Genesis Therapeutics entered a strategic collaboration on the research, discovery and development of novel small-molecule medicines, initially for targets selected by Incyte. The same update says Incyte receives exclusive rights to develop and commercialize collaboration products leveraged through Genesis's GEMS artificial intelligence platform.

Partners: Genesis Therapeutics

AstraZeneca agreed with Tempus and Pathos to build a large multimodal oncology foundation model from clinical and molecular data to support its cancer R&D.

Partners: Tempus, Pathos

Astellas says it has been integrating AI into drug development since 2019 and that its Human-in-the-Loop platform, which combines human expertise, AI and robotics, is widely used in small- and medium-molecule discovery. The article says that by leveraging AI, employees have cut the time to refine a hit compound into a drug candidate by approximately 70% compared with traditional methods.

The same report lists, as a high-value J&J AI use case, an internal chatbot for employees that answers questions on company policies and benefits.

Citing the Wall Street Journal, PYMNTS reports that one of J&J's highest-value AI uses is a generative AI copilot that coaches reps on engaging healthcare professionals.

Amgen's ATOMIC tool ranks candidate trial sites with machine learning, and Amgen reports that top-ranked sites enrolled patients markedly faster.

Sobi's 2024 annual and sustainability report says the DLBCL, ITP and PNH patient councils co-created AI-driven social media campaigns to empower patients and promote shared decision-making with healthcare professionals.

UCB researchers describe FLuID, a federated-learning method for drug discovery, and say that collaborating pharmaceutical companies have improved predictions of how chemical compounds interact with the human body.

Astellas and YASKAWA Electric signed an agreement to establish a joint venture that will develop a cell-therapy manufacturing platform using the Maholo robot. The planned business includes optimizing the digitized manufacturing process with AI and building a platform that meets GMP conditions. Establishment was subject to closing conditions, including regulatory approvals.

Partners: YASKAWA Electric Corporation

Genmab's 2024 annual report describes a partnership with ChatGPT to launch AI Everywhere, so that more than 2,000 colleagues can use ChatGPT.

Partners: ChatGPT

Novo uses AI to find subpopulations, improve trial design and site selection, and forecast outcomes, drawing on harmonized data from about 1,600 trials.

Novo combined AI with high-throughput experiments to assess one billion virtual molecules. The work led to a selective amylin compound.

Teva describes ToMoTo, its topic-modeling tool, as artificial intelligence software that searches medical-affairs databases and compiles a report within three to five minutes.

Daiichi Sankyo said on January 21, 2025 that it had established a San Diego laboratory dedicated to robotics, automation and software for drug discovery. The release says the laboratory will collect data so discovery work can draw on AI, and so scientists can use analytical tools that are based on AI.

Truveta says its member health systems will partner with the Regeneron Genetics Center to sequence up to ten million exomes, and that the de-identified sequencing data added to Truveta Data will let research develop AI that accelerates drug discovery. Truveta reports a $119.5 million Regeneron investment.

Partners: Truveta

Merck's data science and RWE groups agreed to use Atropos Health's platform and services to generate real-world evidence faster.

Partners: Atropos Health

UCB and XtalPi announced a license under which Ailux Biologics grants UCB a non-exclusive license to XtalFold, which the release calls a proprietary AI-based software suite for structural insights in biologics discovery and engineering.

Partners: XtalPi, Ailux Biologics

An expanded collaboration using Valo's human-data and AI platform to discover up to 20 drug programs in obesity, type 2 diabetes and cardiovascular disease.

Partners: Valo Health

PostEra extended its machine-learning drug discovery alliance with Pfizer, adding more small-molecule targets and a new antibody-drug conjugate payload track, for a total potential value of about $610 million.

Partners: PostEra

Sanofi's pharmacovigilance team uses AI and OCR on the IQVIA Vigilance Platform to automate intake of the more than 700,000 adverse reactions it receives each year.

Partners: IQVIA

Gilead and Terray announced a multi-target collaboration using Terray's tNova platform, which combines high-throughput chemistry with a generative AI discovery engine.

Partners: Terray Therapeutics

Takeda's medical writing team built a generative AI prototype to speed compilation of regulatory dossiers by automating analysis of clinical study data. It was being tested on a CSR efficacy section.

Bayer's AI Innovation Platform is a cloud platform, built on Google Cloud, for developing imaging AI and machine-learning healthcare applications. Bayer says it is in external testing.

Partners: Google Cloud

Bayer says Calantic Digital Solutions offers AI-enabled applications that are already available and cleared, orchestrated on one platform for everyday clinical tasks.

MSD worked with the AWS Generative AI Innovation Center on a tool that turns plain-language questions into SQL queries against complex healthcare datasets.

Partners: AWS

Immunai announced a multi-year collaboration with Teva in immunology and immuno-oncology. Immunai says the work will use its AI model, the Immunodynamics Engine, for clinical-trial decisions including mechanism of action, dose selection and biomarker analyses.

Partners: Immunai

An AI tool built jointly by Formation Bio, OpenAI and Sanofi to speed up patient recruitment for clinical trials. Sanofi planned the first deployment in Phase 3 multiple sclerosis studies.

Partners: Formation Bio, OpenAI

BMS describes private in-house ChatGPT and GenAI tools that employees use to upload documents, summarize information, plan projects and find company information.

BMS describes MyGrowth, an AI-enabled internal talent marketplace that matches employees with roles, projects and learning recommendations.

BMS says it uses reinforcement AI to deliver personalized content to physicians through digital channels.

Merck runs an in-house, secured generative AI workspace called GPTeal that gives employees access to several large language models. The CIDO described broad staff adoption in an interview.

Partners: OpenAI, Meta, Anthropic

J&J applies machine learning to large de-identified datasets to find trial sites with eligible patients and to make enrollment faster and more representative.

Engagement.ai is J&J's global machine learning capability that guides when, where and how the company engages healthcare professionals.

J&J analyses demand swings, supplier performance and other data with machine learning to anticipate events that could disrupt product supply.

At its AI Day, BioNTech highlighted InstaDeep's new near-exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale. The release describes this as the introduction of a new near-exascale supercomputer.

At the same AI Day, BioNTech unveiled novel AI Bayesian Flow Network models for protein sequence generation. The release describes the update as the launch of a novel BFN generative model.

InstaDeep's chief executive, speaking as part of BioNTech's AI Day, said a key focus is the DeepChain multiomics design platform. He said DeepChain is now open for external partnerships after successful application to several projects, including the mRNA-encoded antibody RiboMab platform.

BioNTech's AI Day release says the company is highlighting progress in deploying AI across its immunotherapy pipeline, including immunohistochemistry, DNA and RNA sequencing, proteomics, protein design and laboratory functional validation.

AbbVie says large language models let researchers engineer drug candidates in silico rather than relying solely on high-throughput screening.

Generate:Biomedicines announced a multi-target collaboration with Novartis using Generate's generative AI platform to discover protein therapeutics; Generate reports $65 million upfront consideration and potential value above $1 billion.

Partners: Generate:Biomedicines

Gilead and Genesis Therapeutics announced a collaboration using Genesis's GEMS AI platform to generate and jointly optimize molecules against selected targets.

Partners: Genesis Therapeutics

A manufacturing digital transformation program using AI, digital twins and big-data analytics across Takeda plants, including cloud anomaly detection to prevent equipment failures.

Amgen aims for predictive models and digital twins across its manufacturing network; process-parameter monitoring had been shown only in proofs of concept at the time.

Teva's chief medical officer says Teva is using AI for digital-biomarker projects that include a facial-recognition tool for tardive dyskinesia diagnosis (extracting ~500 facial landmarks), an automated speech-based tool relating voice parameters to the PANSS scale, and wearable movement sensors correlated with clinical outcomes in multiple system atrophy.

The same Teva article says AI technology can also be used to select clinical trial sites by combining internal and external data to predict site performance.

The same article says it is also possible to run clinical interviews through an avatar operated by AI, with virtual humans and multimodal interaction for assessment.

Daiichi Sankyo describes DS-GAI as its in-house generative AI system, with chat responses based on files and internal data and with image generation. The July 31, 2024 story says more than half of employees in Japan have experienced it and that the average number of daily users is already over 600.

Takeda's in-house generative AI assistant for summarizing, drafting and analysis. It only sees data that users put into their prompts.

A research alliance using nference machine-learning models on de-identified health records to find IBD patients who could benefit from advanced therapies.

Partners: nference

A three-year extension of a collaboration that applies human genetics and machine learning to drug discovery and development.

Partners: Genomics plc

In its account of operations at Dahej, Torrent's 2023-24 integrated report says that, with an eye on the future, the company is integrating AI, ML and IoT to drive higher automation, optimisation and decision making, setting the stage for Pharma 5.0.

Amgen was an early Microsoft Copilot adopter and expanded access from a small pilot group to about 20,000 employees.

Partners: Microsoft

Amgen installed an NVIDIA supercomputer called Freyja at its deCODE genetics subsidiary to train AI models on its very large store of de-identified human data for research.

Partners: NVIDIA

A custom GPT that uses ChatGPT Enterprise's data-analysis features to help review clinical data for dose selection.

Partners: OpenAI

Moderna rolled out ChatGPT Enterprise company-wide and deployed more than 750 custom GPTs within a few months, across legal, research, manufacturing and commercial.

Partners: OpenAI

United Therapeutics unveiled preliminary findings from its collaboration with Tempus, which it describes as a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.

Partners: Tempus

An on-demand AI model built with Dataiku that analyzes healthcare-provider sentiment in medical-insight data within days.

Partners: Dataiku

Bayer and Aignostics announced a multi-year collaboration to identify novel cancer targets with AI models on multimodal patient data, and to develop AI and machine-learning pathology algorithms that connect pathology and clinical data for trial patient identification, stratification and selection.

Partners: Aignostics

AWS blog co-authored by Gilead's CIO says Gilead uses specialized LLMs to query and summarize literature and databases for drug-target assessment, aiming to cut assessment time by months.

Partners: AWS

Novo runs its own internal ChatGPT and other generative AI tools to raise employee productivity. It listed them in its 2024 Capital Markets Day data-science deck.

An interpretable machine-learning method developed with Microsoft on UK Biobank data to predict atherosclerosis risk and flag new targets and biomarkers.

Partners: Microsoft

A free AI pre-diagnosis tool launched with French start-up MIS that helps doctors identify patients who may have a rare disease.

Partners: Medical Intelligence Service (MIS)